Accumulating evidence suggested that the majority of prevalent pathogenic mechanisms, PTEN/PI3K/Akt, could provide a compelling promise for the treatment of hematologic cancers. The gene discussed is PTEN; the disease is hematopoietic and lymphoid cell neoplasm.